Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AUDA 是可溶性环氧化物水解酶 (sEH) 抑制剂,在小鼠和人 sEH 的IC50分别为 18 和 69 nM,具有抗炎特性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 133 | 现货 | ||
5 mg | ¥ 281 | 现货 | ||
10 mg | ¥ 455 | 现货 | ||
25 mg | ¥ 828 | 现货 | ||
50 mg | ¥ 1,320 | 现货 | ||
100 mg | ¥ 2,120 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 493 | 现货 |
产品描述 | AUDA is an inhibitor of sEH(IC50 values of 18 and 69 nM for the mouse and human enzymes, respectively) |
靶点活性 | sEH:18 nM (mouse), sEH:69 nM (human) |
体外活性 | AUDA significantly inhibited PDGF-induced rat VSMC proliferation, which coincided with Pin1 suppression and heme oxygenase-1 (HO-1) upregulation.?However, exogenous 8,9-EET, 11,12-EET, and 14,15-EET treatments did not alter Pin1 or HO-1 levels and had little effect on the proliferation of rat VSMCs.?On the other hand, AUDA enhanced the PDGF-stimulated cell migration of rat VSMCs.?Furthermore, AUDA-induced activation of cyclooxygenase-2 (COX-2) and subsequent thromboxane A2 (TXA?) production were required for the enhanced migration[1]. |
体内活性 | AUDA increased the proliferation, migration, adhesion and tube formation ability of HCAECs in a dose-dependent manner.?Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1β and TNF-α, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice[2]. |
细胞实验 | Cell Line:Vascular smooth muscle cell (VSMC).Concentration:0.3, 1, 3, 10 μg/mL. Incubation Time:48 hours[1] |
动物实验 | AUDA (i.p.; 10 mg/kg; 14 days) reduces TNF-α, MMP-9 and IL-1β expression levels.Animal Model:Male (wild-type). C57BL/6 mice (age, 4-6 weeks; weight, 18-20 g).Dosage:10 mg/kg.Administration:i.p.; 14 days[2] |
分子量 | 392.58 |
分子式 | C23H40N2O3 |
CAS No. | 479413-70-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/ml (76.41 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5473 mL | 12.7363 mL | 25.4725 mL | 63.6813 mL |
5 mM | 0.5095 mL | 2.5473 mL | 5.0945 mL | 12.7363 mL | |
10 mM | 0.2547 mL | 1.2736 mL | 2.5473 mL | 6.3681 mL | |
20 mM | 0.1274 mL | 0.6368 mL | 1.2736 mL | 3.1841 mL | |
50 mM | 0.0509 mL | 0.2547 mL | 0.5095 mL | 1.2736 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AUDA 479413-70-2 Metabolism Epoxide Hydrolase Inhibitor anti-inflammatory epoxide inhibit hydrolase sEH activity soluble VSMC inhibitor